Novel plasma therapy for covid-19: A Perspective

Authors

  • Chandani Kamble Student, Department of Quality Assurance, Ashokrao Mane College of Pharmacy Peth Vadgaon, Kolhapur, India.
  • Sharad Kamble Assistant Professor, Department of Pharmaceutics, Nootan College of Pharmacy, Kavathemahankal, India.
  • Pragati Pandit Student, Department of Pharmacy, Nootan College of Pharmacy, Kavathemahankal, India.

DOI:

https://doi.org/10.37591/rrjooh.v10i3.2724

Keywords:

Convalescent plasma therapy, Treatment, Covid-19, Middle East respiratory syndrome

Abstract

Coronavirus disease (COVID-19) is an induced disease caused by the coronavirus-19 that causes acute respiratory syndrome (SARS COVID-19). In the month of December 2019, the first case was recorded in Wuhan, China. No specific medications have yet been approved for their treatment; convalescent plasma therapy is projected to boost the survival rate. Early in the twentieth century, convalescent plasma therapy was developed. Convalescent plasma therapy is widely utilized around the world, and it has proven to be effective in saving the lives of COVID-19 patients. Convalescent plasma containing antibodies capable of neutralizing SARS-CoV-2 has shown potential in preventing viral replication and relieving patients' clinical symptoms in preliminary investigations. To definitively elucidate the safety and efficacy of this blood component in COVID-19, the findings of numerous ongoing randomized controlled trials are eagerly awaited. The current evidence from the literature on the treatment of serve COVID-19 with convalescent plasma is summarized in this narrative review.

References

C.G. Chidume, C.N. Oko-Otu, G.C. Aro, State Fragility and COVID-19 pandemic Implications on the political economy of Nigeria, Social Sciences & Humanities Open, 2021:3(1), 2021:100127.

M. Keikha, M. Karbalaei, Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study, New Microbes and New Infections, New Microbes New Infect. 2021 Jul; 42:100901.

Knudson CM, Jackson JB. 6 May 2020. COVID-19 convalescent plasma:phase 2. Transfusion. 2020 Jun; 60(6):1332-1333.

Madariaga MLL, Guthmiller J, Schrantz S, Jansen M, Christenson C, Kumar M, Prochaska M, Wool G, Durkin A, Oh WH, Trockman L, Vigneswaran JKeskey R, Shaw DG, Dugan H, Zheng N, Cobb M, Utset H, Wang J, StovicekO, Bethel C, Matushek S, Giurcanu M, Beavis K, diSabato D, Meltzer D Ferguson M, Kress JP, Shanmugarajah K, Matthews J, Fung J, Wilson P, JC, Donington J. 2020. Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2021 Apr; 289(4):559-573.

Robbiani DF, Gaebler C, Muecksch F, CetruloLorenzi J, Wang Z, Cho A, Agudelo M, Barnes C, Finkin S, Hagglof T, Oliveira T, Viant C, Hurley A,Millard K, Kost R, Cipolla M, Gazumyan A, Gordon K, Bianchini F, ChenS, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Hoffmann H-H,Michailidis E, Ashbrook A, Waltari EF, Pak J, Huey-Tubman K, KorandaN, Hoffman P, West A, Rice C, Hatziioannou T, Bjorkman P, Bieniasz P, Caskey M, Nussenzweig M. 2020. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. Nature. 2020 Aug; 584(7821): 437-442.

Tiberghien P, de Lambalerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how. Vox Sang. 2020; 115(6):488–494.

Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020; 323(16):1561–1562.

Smid WM, Burnouf T, Epstein J, et al. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low-and middle-income countries. Available online at: https://www.isbtweb.org/fileadmin/user_upload/FINAL_Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_in_LMIC.pdf

Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1): 1-22.

Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr; 92(4):418-423.

Tanne JH. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020; 368:m1256.

C Shen, Z Wang, F Zhao, et al. Treatment of 5 Critically Ill Patients with COVID-19 Convalescent Plasma. JAMA. 2020 Apr 28; 323(16):1582-1589.

Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020; 117(17):9490–9496.

Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis.2020; 222(1): Pages 38–43.

Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562.

Downloads

Published

2022-01-05

Issue

Vol. 10 No. 3 (2021)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.